First‐in‐Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease
Open Access
- 22 October 2024
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (6) , 1580-1592
Abstract
Pompe disease is a rare glycogen storage disease caused by mutations in the enzyme acid α‐glucosidase (GAA) resulting in pathological accumulation of glycogen in muscle tissues leading to progressive weakness and respiratory dysfunction. Enzyme replacement therapy (ERT) with GAA is currently the sole treatment option for patients with Pompe disease. ERT burdens patients with frequent intravenous infusions while insufficiently halting disease progression due to incomplete ERT skeletal muscle distribution. Glycogen synthase 1 (GYS1) has been proposed as a substrate reduction therapy (SRT) target for Pompe disease. Here, we report results from the first‐in‐human study of the orally available GYS1 inhibitor MZE001 in healthy subjects. In 88 participants, MZE001 was well‐tolerated up to a single dose of 480 mg BID and multiple doses of 720 mg BID for 10 days. Noncompartmental analysis determined that the half‐life and Ctrough concentrations of MZE001 could provide efficacious exposures with once or twice daily oral dosing. Change from baseline of peripheral blood mononuclear cell (PBMC) glycogen, which correlated with muscle glycogen levels in preclinical models, was significantly reduced dose‐dependently following 10 days of MZE001 treatment in healthy subjects. A muscle biopsy sub‐study demonstrated that 10 days of MZE001 (480 mg BID) dosing safely and substantially lowered muscle glycogen stores in healthy adults. This correlated with the PBMC exposure response and supports the use of PBMC glycogen reduction as a surrogate for muscle response, and MZE001 potential for development as the first oral substrate reduction therapy for patients with Pompe disease.Keywords
This publication has 31 references indexed in Scilit:
- A new phenotype of muscle glycogen synthase deficiency (GSD0B) characterized by an adult onset myopathy without cardiomyopathyNeuromuscular Disorders, 2022
- Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysisJournal of Neurology, 2021
- STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfaJournal of Neurology, 2021
- A well‐tolerated core needle muscle biopsy process suitable for children and adultsMuscle & Nerve, 2020
- Vacuolated PAS‐positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagyJournal of Cellular Physiology, 2017
- Glycogen metabolism in humansBBA Clinical, 2016
- Methodological and physiological test–retest reliability of 13C‐MRS glycogen measurements in liver and in skeletal muscle of patients with type 1 diabetes and matched healthy controlsNMR in Biomedicine, 2016
- Muscle glycogen storage disease 0 presenting recurrent syncope with weakness and myalgiaNeuromuscular Disorders, 2012
- PAS‐positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe diseaseJournal of Inherited Metabolic Disease, 2010
- Liquid Chromatographic Assay for a Glucose Tetrasaccharide, a Putative Biomarker for the Diagnosis of Pompe DiseaseAnalytical Biochemistry, 2000